Fibrosarcoma

Fibrosarcoma is a malignant mesenchymal neoplasm composed of fibroblasts that produces variable amounts of collagen.[1] In the jaws, it may arise as a primary intraosseous (central) tumor or, less commonly, as a peripheral soft tissue mass involving the oral and maxillofacial region.[2][3] The tumor is classified under fibroblastic/myofibroblastic tumors in the 2020 WHO Classification of Tumours of Soft Tissue and Bone, which recognizes adult fibrosarcoma, infantile fibrosarcoma, myxofibrosarcoma, low-grade fibromyxoid sarcoma, and sclerosing epithelioid fibrosarcoma as distinct entities.[4][5] No specific predisposing factors are established, although prior irradiation and pre-existing soft tissue tumors have been associated with some cases.[1][6] Fibrosarcoma is now considered a diagnosis of exclusion; with modern immunohistochemistry and molecular diagnostics, the vast majority of tumors historically classified as fibrosarcoma have been reclassified into other sarcoma subtypes.[7] The characteristic radiographic appearance is a purely radiolucent, destructive bone lesion without intrinsic mineralization.[8] Management centers on wide surgical excision.[1][9]

Current Classification

The 2020 WHO Classification places adult fibrosarcoma (fibrosarcoma, not otherwise specified) within the fibroblastic and myofibroblastic tumor category as a fully malignant neoplasm.[4] Infantile fibrosarcoma is classified separately as an intermediate-grade (rarely metastasizing) tumor.[10]

Related Entities

• Myxofibrosarcoma — previously termed myxoid malignant fibrous histiocytoma; now a distinct WHO entity with prominent myxoid stroma.[4][11]
• Low-grade fibromyxoid sarcoma — a deceptively bland-appearing fibroblastic sarcoma with long-term metastatic potential.[11]
• Sclerosing epithelioid fibrosarcoma — a rare aggressive variant characterized by epithelioid cells in a dense collagenous matrix; MUC4 immunoreactivity is diagnostically useful.[11][12]

Obsolete Terminology

The term "malignant fibrous histiocytoma" (MFH) was formerly applied to many tumors now reclassified as undifferentiated pleomorphic sarcoma, myxofibrosarcoma, or other specific entities.[5][7] Ameloblastic fibrosarcoma is a distinct odontogenic sarcoma and should not be confused with fibrosarcoma of the jaws.[13][14]

• Fibrosarcoma currently accounts for only 1–3% of all sarcomas and represents less than 1% of adult soft tissue sarcomas when strict modern diagnostic criteria are applied.[1][7]
• Among oral and maxillofacial sarcomas, fibrosarcoma constitutes approximately 1.6% of cases, far less common than osteosarcoma, rhabdomyosarcoma, or chondrosarcoma.[6]
• Age: The adult type typically presents in the fourth to sixth decades (mean age approximately 30–50 years in jaw series), while the infantile type develops within the first 2 years of life.[1][9]
• Sex: A slight male predominance has been reported in jaw series.[3][9]
• Site: The mandible is affected more frequently than the maxilla, consistent with the general predilection of oral and maxillofacial sarcomas for the mandible. Approximately 10% of all fibrosarcomas occur in the head and neck. Primary fibrosarcoma of bone shows a strong predilection for long bones; head and neck bones accounted for approximately 15% of cases in the largest historical series.[1][3][6][9]
• Radiation-associated fibrosarcoma has been documented, with a latency period typically exceeding 10 years.[6]

Presentation

• Swelling is the most common presenting sign, often progressive over weeks to months.[6][9][15]
• Pain is frequently present and may be the initial symptom.[9][15]
• Additional findings include paresthesia (particularly inferior alveolar nerve involvement in mandibular lesions), trismus, loosening of teeth, mucosal ulceration, and pathologic fracture.[6][15]

Tempo and Behavior

Fibrosarcoma typically presents as a slow-growing mass, though high-grade tumors may demonstrate more rapid enlargement.[1] Intraosseous lesions may remain clinically occult until substantial bone destruction has occurred. Soft tissue fibrosarcomas of the oral cavity present as submucosal masses that may be firm to hard on palpation.[1][2]

Red Flags

• Unexplained tooth mobility or recent-onset paresthesia in the distribution of the inferior alveolar nerve should raise suspicion for an underlying malignancy.[15][16]
• A history of prior radiation to the head and neck region increases the index of suspicion for radiation-associated sarcoma.[6]
• Dental extractions have been performed before the diagnosis of sarcoma in a substantial proportion of jaw sarcoma patients, underscoring the importance of radiographic evaluation before extraction of teeth with unexplained mobility.[17]

Location and Distribution

• Intraosseous (central) fibrosarcoma of the jaws most commonly involves the body of the mandible, followed by the posterior mandible and maxilla.[2][3][9]
• Periosteal (peripheral) fibrosarcoma arises from the outer cortical surface and is less common in the jaws.[3]
• Soft tissue fibrosarcoma may occur at virtually any oral site, including the gingiva, buccal mucosa, and palate.[1]

Periphery and Shape

• The margin characteristics correlate with histologic grade. Low-grade intraosseous fibrosarcomas characteristically demonstrate relatively well-defined margins, sometimes with a geographic, lobulated, or "soap-bubble" appearance.[18]
• High-grade tumors typically show ill-defined, irregular margins with a wide zone of transition between the lesion and host bone, consistent with a permeative or moth-eaten pattern of osteolysis.[8][18]
• The modified Lodwick-Madewell grading system is useful for characterizing margin aggressiveness: low-grade fibrosarcomas tend to fall into geographic categories (IA–IB), while high-grade tumors demonstrate grade II–III margins.[8][18]

Internal Architecture

• Fibrosarcoma characteristically produces a purely radiolucent (lytic) lesion without intrinsic mineralization, reflecting the fibroblastic cell of origin and absence of osteoid or chondroid matrix production.[8]
• The internal pattern may be homogeneously radiolucent or show coarse trabeculation in low-grade tumors, creating a multilocular or soap-bubble appearance.[18]
• High-grade tumors tend to show a more homogeneously destructive radiolucency without internal septation.[18][19]

Effects on Teeth and Adjacent Structures

• Displacement and loosening of teeth adjacent to the lesion are common findings.[15]
• Root resorption may occur but is not a dominant feature in all cases.
• Widening of the periodontal ligament space of teeth at the periphery of the lesion may be observed, a finding shared with other jaw malignancies.[20]
• Pathologic fracture may occur with extensive bone destruction.[15]

Cortical Involvement and Extent

• Cortical destruction is characteristic, particularly in high-grade tumors, and is a key indicator of malignancy.[19][21]
• Low-grade tumors may demonstrate cortical expansion with thinning rather than frank destruction.[18]
• Extension into adjacent soft tissues is common in advanced lesions and may be appreciated as a soft tissue mass on cross-sectional imaging.[19]
• Periosteal reaction is variable. Unlike osteosarcoma, fibrosarcoma typically does not produce the sunburst or hair-on-end spiculated periosteal patterns. When periosteal reaction is present, it is more commonly lamellated or interrupted (Codman triangle), reflecting aggressive but non-matrix-producing growth.[3][8]

Variants

• Sclerosing epithelioid fibrosarcoma of the jaw has been reported as a periapical radiolucency mimicking a periapical granuloma, highlighting the potential for this rare variant to present with deceptively benign-appearing radiographic features.[12]
• Infantile fibrosarcoma of the jaws is exceedingly rare and typically presents as a soft tissue mass in neonates or infants.[1][22]

CT

• On CT, fibrosarcoma appears as a soft tissue–density mass with heterogeneous attenuation. Intraosseous lesions demonstrate osteolytic bone destruction that may be expansive or frankly permeative depending on grade. CT is superior to MRI for delineating cortical bone destruction and detecting subtle matrix mineralization (which should be absent in true fibrosarcoma).[23][24][25]

MRI

• On T1-weighted images, fibrosarcoma is typically isointense to hypointense relative to muscle.[23][24]
• On T2-weighted images, the tumor characteristically shows heterogeneous signal with areas of mild hypointensity, a feature attributed to dense collagen content and fibrous septation. Band-like areas of low signal on all sequences, corresponding to fibrous septa, may be a useful diagnostic clue.[10][23][24]
• Contrast-enhanced MRI demonstrates marked heterogeneous delayed enhancement. Peripheral enhancement and spoke-wheel–like enhancement patterns have been described.[23][24]
• MRI is the preferred modality for assessing intramedullary extent, soft tissue involvement, and neurovascular relationships.[21][25]

PET/CT

• FDG-PET/CT may be useful for staging, detecting distant metastases, and monitoring treatment response in soft tissue sarcomas, including fibrosarcoma.[4][26]

The differential diagnosis of a purely lytic, destructive jaw lesion without intrinsic mineralization centers on distinguishing fibrosarcoma from other malignant and aggressive entities that share overlapping radiographic features. The absence of tumor matrix mineralization is the most important feature separating fibrosarcoma from osteosarcoma and chondrosarcoma.

The highest-risk diagnostic pitfall is misidentifying a fibroblastic osteosarcoma as fibrosarcoma, since fibroblastic osteosarcoma may produce minimal osteoid that is detectable only on thorough histologic sampling. Biopsy with assessment by an experienced sarcoma pathologist, including immunohistochemistry and molecular studies to exclude monophasic synovial sarcoma (SYT rearrangement), malignant peripheral nerve sheath tumor (S-100), and other mimics, is essential before definitive treatment.[4][7]

Microscopic Features

• The hallmark is a monomorphic proliferation of spindle-shaped fibroblasts arranged in long, sweeping fascicles that intersect at acute angles, producing the classic herringbone pattern.[1][2]
• Nuclear pleomorphism is typically mild to moderate; mitotic figures are always present but vary in number with tumor grade.[1][29]
• Collagen production is variable but usually limited; the stroma lacks osteoid, chondroid, or other specialized matrix.[1][3]

Immunohistochemistry

• Tumor cells are positive for vimentin and may show focal smooth muscle actin reactivity.[1][2]
• Characteristically negative for S-100 protein, cytokeratins, EMA, CD34, desmin, HMB-45, and myogenic markers — a critical panel for excluding morphologic mimics.[2][29]
• MIB-1 (Ki-67) proliferation index is typically elevated.[2]

Grading

• The FNCLCC grading system (differentiation, mitotic count, necrosis) is applied and strongly correlates with prognosis.[4][18]
• Low-grade tumors (FNCLCC grade 1) show lower cellularity, fewer mitoses, and no necrosis; high-grade tumors (grade 2–3) demonstrate increased cellularity, brisk mitotic activity, and necrosis.[3][18]

Radiologic-Pathologic Correlation

The purely lytic radiographic appearance without mineralization directly reflects the fibroblastic histogenesis and absence of osteoid or chondroid matrix production.[8] Well-defined radiographic margins correlate with low histologic grade, while permeative destruction corresponds to high-grade tumors.[18]

Molecular Findings

• Multiple chromosomal abnormalities have been reported, but only alterations at 2q14–22 have been consistently identified.[1]
• No pathognomonic translocation exists for adult fibrosarcoma, distinguishing it from infantile fibrosarcoma (which harbors the ETV6::NTRK3 fusion from t(12;15)).[10][30]
• The absence of a defining molecular signature reinforces fibrosarcoma's status as a diagnosis of exclusion; molecular testing is primarily used to rule out other entities (e.g., SYT::SSX in synovial sarcoma, EWSR1::FLI1 in Ewing sarcoma).[7]

Workup and Referral

• All patients with suspected jaw sarcoma should be evaluated by a multidisciplinary team with sarcoma expertise before initiation of therapy.[4]
• Cross-sectional imaging (MRI with and without contrast and/or CT with contrast) of the primary tumor is essential for surgical planning.[4]
• Chest CT is indicated to evaluate for pulmonary metastases, the most common site of distant spread.[9][21]
• Core needle biopsy (preferred) or incisional biopsy should be performed after adequate imaging, placed along the anticipated resection axis.[4]

Definitive Treatment

• Wide surgical excision with negative margins is the mainstay of treatment. In the jaws, this typically requires segmental mandibulectomy or partial maxillectomy with mandibular reconstruction.[1][2][9][17][31]
• Achieving adequate surgical margins in the head and neck is challenging due to anatomic constraints; positive or close margins are the most important predictor of local recurrence.[17]
• Adjuvant radiotherapy is commonly administered, particularly when wide margins cannot be achieved.[32][33]
• The role of chemotherapy remains uncertain for adult fibrosarcoma of the jaws. Neoadjuvant or adjuvant chemotherapy may be considered for high-grade tumors, though response rates for head and neck sarcomas are limited.[4][17]

Recurrence and Metastasis

• Local recurrence rates are high, ranging from 42% to 79% depending on margin adequacy.[1]
• The metastatic rate ranges from 32% to 82% and is strongly grade-dependent; the lungs are the predominant site of distant metastasis.[1][9]
• All patients with unfavorable outcomes in the largest jaw series developed lung metastases.[9]

Prognosis

• The 5-year survival rate for fibrosarcoma of the jaws is approximately 71%, which is more favorable than fibrosarcoma at other skeletal sites or osteosarcoma of the jaws.[9]
• For primary fibrosarcoma of bone overall, 5-year survival is approximately 34%, with periosteal tumors (52%) faring better than medullary tumors (27%).[3]
• Key prognostic factors include histologic grade (the strongest predictor), margin status, and tumor size.[18][32][34]
• Low-grade tumors carry a significantly better prognosis than high-grade lesions.[18][34]

Surveillance

• Follow-up with clinical examination and imaging every 3–6 months for 3 years, then every 6 months to complete 5 years, then annually. Chest[4]